Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer

► We detected no difference in either progression free or overall survival between patients who required dose adjustments and treatment delays and those who did not. ► As seen in other cancers, the most common reasons for chemotherapy delays/reductions were neutropenia, thrombocytopenia, and neuropathy.